Quick Answer
Syndax Pharmaceuticals Inc reported Net Income of -$285.42 million for fiscal year 2025.
Syndax Pharmaceuticals Inc Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$285.42M | +10.5% |
| 2024 | -$318.76M | -52.3% |
| 2023 | -$209.36M | -40.2% |
| 2022 | -$149.34M | -699.1% |
| 2021 | $24.93M | +134.1% |
| 2020 | -$73.16M | -30.5% |
| 2019 | -$56.05M | +24.2% |
| 2018 | -$73.96M | -21.6% |
| 2017 | -$60.80M | -36.7% |
| 2016 | -$44.47M | -84.4% |
| 2015 | -$24.12M | -21.6% |
| 2014 | -$19.83M | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$60.72M | +27.8% | +15.5% |
| June 30, 2025 | -$71.85M | -5.6% | +15.3% |
| March 31, 2025 | -$84.85M | -17.2% | -0.9% |
| September 30, 2024 | -$84.13M | -64.5% | -23.6% |
| June 30, 2024 | -$68.06M | -52.6% | +6.0% |
| March 31, 2024 | -$72.40M | -76.0% | -41.6% |
| September 30, 2023 | -$51.15M | -44.5% | -14.6% |
| June 30, 2023 | -$44.62M | -18.7% | -8.5% |
- Syndax Pharmaceuticals Inc showed an increase of +10.5% in Net Income compared to the prior fiscal year.
- Over the 2014–2025 period, Syndax Pharmaceuticals Inc’s net income has declined by 1339.5% (from -$19.83 million to -$285.42 million).
- The most recent figure is from Syndax Pharmaceuticals Inc’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: